-
公开(公告)号:US20220148997A1
公开(公告)日:2022-05-12
申请号:US17433768
申请日:2020-02-27
申请人: IMMUNOLIGHT, LLC
发明人: Frederic A. BOURKE, Jr. , Harold WALDER , Zakaryae FATHI , Wayne F. BEYER , Ronald A. RUDDER , Joseph H. SIMMONS
IPC分类号: H01L23/00 , C09K11/02 , C09J133/08
摘要: An emission enhancement structure having at least one energy augmentation structure; and an energy converter capable of receiving energy from an energy source, converting the energy and emitting therefrom a light of a different energy than the received energy. The energy converter is disposed in a vicinity of the at least one energy augmentation structure such that the emitted light is emitted with an intensity larger than if the converter were remote from the at least one energy augmentation structure. Also described are various uses for the energy emitters, energy augmentation structures and energy collectors in a wide array of fields, including various adhesives applications.
-
92.
公开(公告)号:US11278861B2
公开(公告)日:2022-03-22
申请号:US16900091
申请日:2020-06-12
申请人: IMMUNOLIGHT, LLC , DUKE UNIVERSITY
IPC分类号: B01J19/12 , A23L3/26 , A61L2/00 , C02F1/30 , C02F1/72 , A23L5/30 , B01J19/08 , A61L2/08 , A61L2/10 , A61L2/16 , C08J3/28 , G21K5/00 , C02F1/32 , A61K41/00 , A61N5/06 , A61N5/10 , B01J23/50 , B01J23/52 , B01J31/02 , B01J31/22 , B01J35/00 , B01J37/00 , B01J37/02 , C09D201/00 , C09J5/00 , C09J201/00 , A23L2/50 , A23L3/28 , C08J3/24 , C08J7/18 , G02B5/00 , A61M1/36 , C12H1/06 , B82Y20/00 , B82Y30/00 , B82Y40/00
摘要: A method and a system for producing a change in a medium disposed in an artificial container. The method places in a vicinity of the medium at least one of a plasmonics agent and an energy modulation agent. The method applies an initiation energy through the artificial container to the medium. The initiation energy interacts with the plasmonics agent or the energy modulation agent to directly or indirectly produce the change in the medium. The system includes an initiation energy source configured to apply an initiation energy to the medium to activate the plasmonics agent or the energy modulation agent.
-
93.
公开(公告)号:US20210353954A1
公开(公告)日:2021-11-18
申请号:US17443981
申请日:2021-07-29
申请人: IMMUNOLIGHT, LLC
IPC分类号: A61N5/06 , A61K31/015 , A61K31/37 , A61K31/519 , A61K41/00 , A61M31/00 , A61N1/40
摘要: A system and method for emitting a wavelength of energy internal to a medium or internal to a human or animal subject, and methods for using the system in the treatment of a condition, disorder, or disease. The system includes 1) a source configured to produce an initiation signal penetrating at least a part of the medium or the human or animal subject and 2) an insertion device having an electronics assembly unit. The assembly unit includes 1) an emitter configured to emit the wavelength of energy of a predetermined type to treat a disease or disorder in the human or animal subject or to produce a change in the medium and 2) a receiver that receives the signal.
-
公开(公告)号:US10974493B2
公开(公告)日:2021-04-13
申请号:US15896654
申请日:2018-02-14
申请人: IMMUNOLIGHT, LLC
发明人: Zakaryae Fathi
IPC分类号: B32B38/00 , C09J5/00 , C09J133/12 , B32B37/00 , B32B37/12 , C09J5/04 , C09J11/04 , C09J157/00 , C08K3/00 , C08K3/22
摘要: A reactive polymer composition is provided, containing a (co)polymer that forms one or more reactive moities, either directly or indirectly, upon application of an ionizing radiation; and a multifunctional curing coagent, along with systems and methods for bonding substrates to one another using such a composition.
-
公开(公告)号:US10940329B2
公开(公告)日:2021-03-09
申请号:US15819130
申请日:2017-11-21
申请人: IMMUNOLIGHT, LLC , DUKE UNIVERSITY
发明人: Mark Oldham , Justus Adamson , Paul Yoon , Harold Walder , Frederic A. Bourke, Jr. , Zakaryae Fathi , Wayne F. Beyer
IPC分类号: A61K49/00 , A61N5/10 , C09K11/59 , C09K11/73 , C09K11/02 , A61K31/37 , A61P35/00 , A61K41/00 , A61K49/04
摘要: A phosphor-containing drug activator activatable from a Monte Carlo derived x-ray exposure for treatment of a diseased site. The activator includes an admixture or suspension of one or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays, wherein a distribution of the phosphors in the diseased target site is based on a Monte Carlo derived x-ray dose. A system for treating a disease in a subject in need thereof, includes the drug activator and a photoactivatable drug, one or more devices which infuse the photoactivatable drug and the activator including the pharmaceutically acceptable carrier into a diseased site in the subject; and an x-ray source which is controlled to deliver the Monte Carlo derived x-ray exposure to the subject for production of ultraviolet and visible light inside the subject to activate the photoactivatable drug.
-
公开(公告)号:US20200323711A1
公开(公告)日:2020-10-15
申请号:US16915058
申请日:2020-06-29
申请人: Immunolight, LLC
IPC分类号: A61F13/551 , A61F13/20 , A61F13/26
摘要: A light emitting composition including first color emitters and second color emitters. The first color emitters are configured to emit, upon exposure to an energy source, visible light at a target color in response to absorption of energy across a first band of wavelengths. The second color emitters are configured to emit, upon exposure to the energy source, visible light at the target color in response to absorption of energy across a second band of wavelengths. The light intensity observable at the target color is enhanced relative to reflected white light without emission from the first and second color emitters. The light emitting composition can be a part of a paint, an ink, a fabric, a thread, a road sign, a highway marking, an automobile, a boat, a plane, a reflector, a building product, a concrete product, an epoxy product, a jewelry product, colored contact lens, a candle product, a rubber product, a plastic product, or other colored surface.
-
公开(公告)号:US20200222711A1
公开(公告)日:2020-07-16
申请号:US16728803
申请日:2019-12-27
申请人: IMMUNOLIGHT, LLC. , DUKE UNIVERSITY
发明人: Harold WALDER , Frederic A. Bourke, JR. , Zakaryae Fathi , Wayne F. Beyer, JR. , Mark Dewhirst , Mark Oldham , Justus Adamson , Michael Nolan
摘要: A system and method for imaging or treating a disease in a human or animal body. The system provides to the human or animal body a pharmaceutical carrier including one or more phosphors which are capable of emitting ultraviolet or visible light into the body and which provide x-ray contrast. The system includes one or more devices which infuse a diseased site with a photoactivatable drug and the pharmaceutical carrier, an initiation energy source comprising an x-ray or high energy source which irradiates the diseased site with at least one of x-rays, gamma rays, or electrons to thereby initiate emission of said ultraviolet or visible light into the body, and a processor programmed to at least one of 1) produce images of the diseased site or 2) control a dose of said x-rays, gamma rays, or electrons to the diseased site for production of said ultraviolet or visible light at the diseased site to activate the photoactivatable drug.
-
公开(公告)号:US10596387B2
公开(公告)日:2020-03-24
申请号:US15307766
申请日:2015-04-22
申请人: IMMUNOLIGHT, LLC. , DUKE UNIVERSITY
发明人: Harold Walder , Frederic A. Bourke , Zakaryae Fathi , Wayne F. Beyer , Mark W. Dewhirst , Mark Oldham , Justus Adamson , Michael Nolan
摘要: A system and method for imaging or treating a disease in a human or animal body. The system provides to the human or animal body a pharmaceutical carrier including one or more phosphors which are capable of emitting ultraviolet or visible light into the body and which provide x-ray contrast. The system includes one or more devices which infuse a diseased site with a photoactivatable drug and the pharmaceutical carrier, an initiation energy source comprising an x-ray or high energy source which irradiates the diseased site with at least one of x-rays, gamma rays, or electrons to thereby initiate emission of said ultraviolet or visible light into the body, and a processor programmed to at least one of 1) produce images of the diseased site or 2) control a dose of said x-rays, gamma rays, or electrons to the diseased site for production of said ultraviolet or visible light at the diseased site to activate the photoactivatable drug.
-
公开(公告)号:US20200078600A1
公开(公告)日:2020-03-12
申请号:US16516463
申请日:2019-07-19
申请人: Immunolight, LLC. , Duke University
发明人: Tuan VO-DINH , Jonathan P. SCAFFIDI , Venkata Gopal Reddy CHADA , Benoit LAULY , Yan ZHANG , Molly K. GREGAS , Ian Nicholas STANTON , Joshua T. STECHER , Michael J. THERIEN , Frederic A. BOURKE, JR. , Harold WALDER , Zak FATHI , Jennifer A. AYRES , Zhenyuan ZHANG , Joseph H. SIMMONS , Stephen John NORTON
IPC分类号: A61N5/06 , A61K49/00 , A61N1/40 , A61N5/02 , A61B5/00 , A61B5/055 , A61B6/00 , A61K41/00 , A61M5/00 , A61L2/00
摘要: Products, compositions, systems, and methods for modifying a target structure which mediates or is associated with a biological activity, including treatment of conditions, disorders, or diseases mediated by or associated with a target structure, such as a virus, cell, subcellular structure or extracellular structure. The methods may be performed in situ in a non-invasive manner by placing a nanoparticle having a metallic shell on at least a fraction of a surface in a vicinity of a target structure in a subject and applying an initiation energy to a subject thus producing an effect on or change to the target structure directly or via a modulation agent. The nanoparticle is configured, upon exposure to a first wavelength λ1, to generate a second wavelength λ2 of radiation having a higher energy than the first wavelength λ1. The methods may further be performed by application of an initiation energy to a subject in situ to activate a pharmaceutical agent directly or via an energy modulation agent, optionally in the presence of one or more plasmonics active agents, thus producing an effect on or change to the target structure. Kits containing products or compositions formulated or configured and systems for use in practicing these methods.
-
公开(公告)号:US20190336786A1
公开(公告)日:2019-11-07
申请号:US16511605
申请日:2019-07-15
申请人: Immunolight, LLC. , Duke University
摘要: Products, compositions, systems, and methods for modifying a target structure which mediates or is associated with a biological activity, including treatment of conditions, disorders, or diseases mediated by or associated with a target structure, such as a virus, cell, subcellular structure or extracellular structure. The methods may be performed in situ in a non-invasive manner by application of an initiation energy to a subject thus producing an effect on or change to the target structure directly or via a modulation agent. The methods may further be performed by application of an initiation energy to a subject in situ to activate a pharmaceutical agent directly or via an energy modulation agent, optionally in the presence of one or more plasmonics active agents, thus producing an effect on or change to the target structure. Kits containing products or compositions formulated or configured and systems for use in practicing these methods.
-
-
-
-
-
-
-
-
-